

CLAIMS AFTER AMENDMENT**In the Claims:**

1-59 Cancelled.

60. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in any of Figures 1, 3 or 4, wherein said polynucleotide has a maximum length of 353 nucleotides.

61. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in any of Figures 1, 3 or 4, wherein said polynucleotide has a maximum length of 586 nucleotides.

62. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in any of the viral cDNA inserts in a lambda gt-11 cDNA library deposited as ATCC No. 40394, wherein said polynucleotide has a maximum length of 353 nucleotides.

63. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in any of the viral cDNA inserts in a lambda gt-11 cDNA library deposited as ATCC No. 40394, wherein said polynucleotide has a maximum length of 586 nucleotides.

5
64. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 14, wherein said polynucleotide has a maximum length of 353 nucleotides.

6
65. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 14, wherein said polynucleotide has a maximum length of 586 nucleotides.

7
66. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 26, wherein said polynucleotide has a maximum length of 353 nucleotides.

8
67. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 26, wherein said polynucleotide has a maximum length of 586 nucleotides.

9
68. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figures 57, wherein said polynucleotide has a maximum length of 353 nucleotides.

10
69. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the

nucleotide sequence in Figure 57, wherein said polynucleotide has a maximum length of 586 nucleotides.

70.¹¹ (Previously Amended) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 59 or the nucleotide sequence shown in Figure 62 or the complement thereof, wherein said polynucleotide has a maximum length of 353 nucleotides.

71.¹² (Previously Amended) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 59 or the nucleotide sequence shown in Figure 62 or the complement thereof, wherein said polynucleotide has a maximum length of 586 nucleotides.

72.¹³ (Previously Amended) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 72 or the nucleotide sequence shown in Figure 89 or the complement thereof, wherein said polynucleotide has a maximum length of 353 nucleotides.

73.¹⁴ (Previously Amended) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 72 or the nucleotide sequence shown in Figure 89 or the complement thereof, wherein said polynucleotide has a maximum length of 586 nucleotides.

74.¹⁵ (Previously Presented) A polynucleotide according to any one of claims ~~60-73~~¹⁻¹⁴, wherein said contiguous sequence is at least 10 nucleotides.

67
75. (Previously Presented) A polynucleotide according to any one of claims 60-73, wherein said contiguous sequence is at least 12 nucleotides.

119
76. (Previously Presented) A polynucleotide according to any one of claims 60-73, wherein said contiguous sequence is at least 15 nucleotides.

170
77. (Previously Presented) A polynucleotide according to any one of claims 60-73, wherein said contiguous sequence is at least 20 nucleotides.

223
78. (Previously Presented) A polynucleotide according to any of claims 60-73 wherein said polynucleotide has a maximum length of 161 nucleotides.

14
79. (Previously Presented) A polynucleotide according to claim 74 wherein said polynucleotide has a maximum length of 161 nucleotides.

68
80. (Previously Presented) A polynucleotide according to claim 75 wherein said polynucleotide has a maximum length of 161 nucleotides.

20
81. (Previously Presented) A polynucleotide according to claim 76 wherein said polynucleotide has a maximum length of 161 nucleotides.

71
82. (Previously Presented) A polynucleotide according to claim 71 wherein said polynucleotide has a maximum length of 161 nucleotides.

239
83. (Previously Presented) A polynucleotide according to any of claims 60-73 wherein said polynucleotide has a maximum length of 108 nucleotides.

33
84. (Previously Presented) A polynucleotide according to claim 74 wherein said polynucleotide has a maximum length of 108 nucleotides.

86
85. (Previously Presented) A polynucleotide according to claim 75 wherein said polynucleotide has a maximum length of 108 nucleotides.

137
86. (Previously Presented) A polynucleotide according to claim 76 wherein said polynucleotide has a maximum length of 108 nucleotides.

188
87. (Previously Presented) A polynucleotide according to claim 77 wherein said polynucleotide has a maximum length of 108 nucleotides.

257
88. (Previously Presented) A polynucleotide according to any of claims 60-73 wherein said polynucleotide is single stranded.

51
89. (Previously Presented) A polynucleotide according to claim 74 wherein said polynucleotide is single stranded.

103
90. (Previously Presented) A polynucleotide according to claim 75 wherein said polynucleotide is single stranded.

154
91. (Previously Presented) A polynucleotide according to claim 76 wherein said polynucleotide is single stranded.

204
92. (Previously Presented) A polynucleotide according to claim 77 wherein said polynucleotide is single stranded.

273
93. (Previously Presented) A polynucleotide according to claim 78 wherein said polynucleotide is single stranded.

17
94. (Previously Presented) A polynucleotide according to claim 79 wherein said polynucleotide is single stranded.

- 69
95. (Previously Presented) A polynucleotide according to claim 80 wherein said polynucleotide is single stranded.
- 121
96. (Previously Presented) A polynucleotide according to claim 81 wherein said polynucleotide is single stranded.
- 172
97. (Previously Presented) A polynucleotide according to claim 82 wherein said polynucleotide is single stranded.
- 240
98. (Previously Presented) A polynucleotide according to claim 83 wherein said polynucleotide is single stranded.
- 34
99. (Previously Presented) A polynucleotide according to claim 84 wherein said polynucleotide is single stranded.
- 87
100. (Previously Presented) A polynucleotide according to claim 85 wherein said polynucleotide is single stranded.
- 38
101. (Previously Presented) A polynucleotide according to claim 86 wherein said polynucleotide is single stranded.
- 159
102. (Previously Presented) A polynucleotide according to claim 87 wherein said polynucleotide is single stranded.
- 265
103. (Previously Presented) A polynucleotide according to any of claims 60-73 wherein said polynucleotide is DNA.
- 58
104. (Previously Presented) A polynucleotide according to claim 74 wherein said polynucleotide is DNA.

110
105. (Previously Presented) A polynucleotide according to claim 75 wherein said polynucleotide is DNA.

111
106. (Previously Presented) A polynucleotide according to claim 76 wherein said polynucleotide is DNA.

113
107. (Previously Presented) A polynucleotide according to claim 77 wherein said polynucleotide is DNA.

110
108. (Previously Presented) A polynucleotide according to claim 78 wherein said polynucleotide is DNA.

111
109. (Previously Presented) A polynucleotide according to claim 79 wherein said polynucleotide is DNA.

112
110. (Previously Presented) A polynucleotide according to claim 80 wherein said polynucleotide is DNA.

112
111. (Previously Presented) A polynucleotide according to claim 81 wherein said polynucleotide is DNA.

112
112. (Previously Presented) A polynucleotide according to claim 82 wherein said polynucleotide is DNA.

113
113. (Previously Presented) A polynucleotide according to claim 83 wherein said polynucleotide is DNA.

114
114. (Previously Presented) A polynucleotide according to claim 84 wherein said polynucleotide is DNA.

94
115. (Previously Presented) A polynucleotide according to claim 85 wherein said polynucleotide is DNA.

145
116. (Previously Presented) A polynucleotide according to claim 86 wherein said polynucleotide is DNA.

197
117. (Previously Presented) A polynucleotide according to claim 87 wherein said polynucleotide is DNA.

258
118. (Previously Presented) A polynucleotide according to claim 88 wherein said polynucleotide is DNA.

52
119. (Previously Presented) A polynucleotide according to claim 89 wherein said polynucleotide is DNA.

104
120. (Previously Presented) A polynucleotide according to claim 90 wherein said polynucleotide is DNA.

155
121. (Previously Presented) A polynucleotide according to claim 91 wherein said polynucleotide is DNA.

207
122. (Previously Presented) A polynucleotide according to claim 92 wherein said polynucleotide is DNA.

224
123. (Previously Presented) A polynucleotide according to claim 93 wherein said polynucleotide is DNA.

18
124. (Previously Presented) A polynucleotide according to claim 94 wherein said polynucleotide is DNA.

- 10
125. (Previously Presented) A polynucleotide according to claim 95 wherein said polynucleotide is DNA.
126. (Previously Presented) A polynucleotide according to claim 96 wherein said polynucleotide is DNA.
127. (Previously Presented) A polynucleotide according to claim 97 wherein said polynucleotide is DNA.
128. (Previously Presented) A polynucleotide according to claim 98 wherein said polynucleotide is DNA.
129. (Previously Presented) A polynucleotide according to claim 99 wherein said polynucleotide is DNA.
130. (Previously Presented) A polynucleotide according to claim 100 wherein said polynucleotide is DNA.
131. (Previously Presented) A polynucleotide according to claim 101 wherein said polynucleotide is DNA.
132. (Previously Presented) A polynucleotide according to claim 102 wherein said polynucleotide is DNA.
133. (Previously Presented) A polynucleotide according to any of claims 60-73 wherein said polynucleotide is labeled.
134. (Previously Presented) A polynucleotide according to claim 74 wherein said polynucleotide is labeled.

112
135. (Previously Presented) A polynucleotide according to claim 75 wherein said polynucleotide is labeled.

163
136. (Previously Presented) A polynucleotide according to claim 76 wherein said polynucleotide is labeled.

215
137. (Previously Presented) A polynucleotide according to claim 77 wherein said polynucleotide is labeled.

232
138. (Previously Presented) A polynucleotide according to claim 78 wherein said polynucleotide is labeled.

26
139. (Previously Presented) A polynucleotide according to claim 79 wherein said polynucleotide is labeled.

79
140. (Previously Presented) A polynucleotide according to claim 80 wherein said polynucleotide is labeled.

130
141. (Previously Presented) A polynucleotide according to claim 81 wherein said polynucleotide is labeled.

181
142. (Previously Presented) A polynucleotide according to claim 82 wherein said polynucleotide is labeled.

247
143. (Previously Presented) A polynucleotide according to claim 83 wherein said polynucleotide is labeled.

44
144. (Previously Presented) A polynucleotide according to claim 84 wherein said polynucleotide is labeled.

145. (Previously Presented) A polynucleotide according to claim 85 wherein said polynucleotide is labeled. 86
146. (Previously Presented) A polynucleotide according to claim 86 wherein said polynucleotide is labeled. 137
147. (Previously Presented) A polynucleotide according to claim 87 wherein said polynucleotide is labeled. 188
148. (Previously Presented) A polynucleotide according to claim 88 wherein said polynucleotide is labeled. 257
149. (Previously Presented) A polynucleotide according to claim 89 wherein said polynucleotide is labeled. 51
150. (Previously Presented) A polynucleotide according to claim 90 wherein said polynucleotide is labeled. 103
151. (Previously Presented) A polynucleotide according to claim 91 wherein said polynucleotide is labeled. 154
152. (Previously Presented) A polynucleotide according to claim 92 wherein said polynucleotide is labeled. 204
153. (Previously Presented) A polynucleotide according to claim 93 wherein said polynucleotide is labeled. 273
154. (Previously Presented) A polynucleotide according to claim 94 wherein said polynucleotide is labeled. 17

172 69
155. (Previously Presented) A polynucleotide according to claim 95 wherein said polynucleotide is labeled.

174 121
156. (Previously Presented) A polynucleotide according to claim 96 wherein said polynucleotide is labeled.

175 172
157. (Previously Presented) A polynucleotide according to claim 97 wherein said polynucleotide is labeled.

173 240
158. (Previously Presented) A polynucleotide according to claim 98 wherein said polynucleotide is labeled.

37 34
159. (Previously Presented) A polynucleotide according to claim 99 wherein said polynucleotide is labeled.

90 87
160. (Previously Presented) A polynucleotide according to claim 100 wherein said polynucleotide is labeled.

141 138
161. (Previously Presented) A polynucleotide according to claim 101 wherein said polynucleotide is labeled.

192 159
162. (Previously Presented) A polynucleotide according to claim 102 wherein said polynucleotide is labeled.

264 265
163. (Previously Presented) A polynucleotide according to claim 103 wherein said polynucleotide is labeled.

59 56
164. (Previously Presented) A polynucleotide according to claim 104 wherein said polynucleotide is labeled.

165. (Previously Presented) A polynucleotide according to claim 105 wherein said polynucleotide is labeled.

166. (Previously Presented) A polynucleotide according to claim 106 wherein said polynucleotide is labeled.

167. (Previously Presented) A polynucleotide according to claim 107 wherein said polynucleotide is labeled.

168. (Previously Presented) A polynucleotide according to claim 108 wherein said polynucleotide is labeled.

169. (Previously Presented) A polynucleotide according to claim 109 wherein said polynucleotide is labeled.

170. (Previously Presented) A polynucleotide according to claim 110 wherein said polynucleotide is labeled.

171. (Previously Presented) A polynucleotide according to claim 111 wherein said polynucleotide is labeled.

172. (Previously Presented) A polynucleotide according to claim 112 wherein said polynucleotide is labeled.

173. (Previously Presented) A polynucleotide according to claim 113 wherein said polynucleotide is labeled.

174. (Previously Presented) A polynucleotide according to claim 114 wherein said polynucleotide is labeled.

95
175. (Previously Presented) A polynucleotide according to claim 115 wherein said polynucleotide is labeled.

146
176. (Previously Presented) A polynucleotide according to claim 116 wherein said polynucleotide is labeled.

198
177. (Previously Presented) A polynucleotide according to claim 117 wherein said polynucleotide is labeled.

259
178. (Previously Presented) A polynucleotide according to claim 118 wherein said polynucleotide is labeled.

53
179. (Previously Presented) A polynucleotide according to claim 119 wherein said polynucleotide is labeled.

105
180. (Previously Presented) A polynucleotide according to claim 120 wherein said polynucleotide is labeled.

156
181. (Previously Presented) A polynucleotide according to claim 121 wherein said polynucleotide is labeled.

208
182. (Previously Presented) A polynucleotide according to claim 122 wherein said polynucleotide is labeled.

225
183. (Previously Presented) A polynucleotide according to claim 123 wherein said polynucleotide is labeled.

119
184. (Previously Presented) A polynucleotide according to claim 124 wherein said polynucleotide is labeled.

11 10
185. (Previously Presented) A polynucleotide according to claim 125 wherein said polynucleotide is labeled.

123 122
186. (Previously Presented) A polynucleotide according to claim 126 wherein said polynucleotide is labeled.

174 173
187. (Previously Presented) A polynucleotide according to claim 127 wherein said polynucleotide is labeled.

242 241
188. (Previously Presented) A polynucleotide according to claim 128 wherein said polynucleotide is labeled.

34 35
189. (Previously Presented) A polynucleotide according to claim 129 wherein said polynucleotide is labeled.

89 88
190. (Previously Presented) A polynucleotide according to claim 130 wherein said polynucleotide is labeled.

140 139
191. (Previously Presented) A polynucleotide according to claim 131 wherein said polynucleotide is labeled.

191 190
192. (Previously Presented) A polynucleotide according to claim 132 wherein said polynucleotide is labeled.

269 1-14
193. (Previously Presented) A polynucleotide according to any of claims 60-73 wherein said polynucleotide is RNA.

61 15
194. (Previously Presented) A polynucleotide according to claim 74 wherein said polynucleotide is RNA.

113 67
195. (Previously Presented) A polynucleotide according to claim 75 wherein said polynucleotide is RNA.

164 119
196. (Previously Presented) A polynucleotide according to claim 76 wherein said polynucleotide is RNA.

216 170
197. (Previously Presented) A polynucleotide according to claim 77 wherein said polynucleotide is RNA.

233 222
198. (Previously Presented) A polynucleotide according to claim 78 wherein said polynucleotide is RNA.

27 16
199. (Previously Presented) A polynucleotide according to claim 79 wherein said polynucleotide is RNA.

80 68
200. (Previously Presented) A polynucleotide according to claim 80 wherein said polynucleotide is RNA.

131 120
201. (Previously Presented) A polynucleotide according to claim 81 wherein said polynucleotide is RNA.

182 171
202. (Previously Presented) A polynucleotide according to claim 82 wherein said polynucleotide is RNA.

25 739
203. (Previously Presented) A polynucleotide according to claim 83 wherein said polynucleotide is RNA.

45 33
204. (Previously Presented) A polynucleotide according to claim 84 wherein said polynucleotide is RNA.

97
205. (Previously Presented) A polynucleotide according to claim 85 wherein said polynucleotide is RNA.

148
206. (Previously Presented) A polynucleotide according to claim 86 wherein said polynucleotide is RNA.

200
207. (Previously Presented) A polynucleotide according to claim 87 wherein said polynucleotide is RNA.

261
208. (Previously Presented) A polynucleotide according to claim 88 wherein said polynucleotide is RNA.

55
209. (Previously Presented) A polynucleotide according to claim 89 wherein said polynucleotide is RNA.

107
210. (Previously Presented) A polynucleotide according to claim 90 wherein said polynucleotide is RNA.

158
211. (Previously Presented) A polynucleotide according to claim 91 wherein said polynucleotide is RNA.

210
212. (Previously Presented) A polynucleotide according to claim 92 wherein said polynucleotide is RNA.

227
213. (Previously Presented) A polynucleotide according to claim 93 wherein said polynucleotide is RNA.

21
214. (Previously Presented) A polynucleotide according to claim 94 wherein said polynucleotide is RNA.

13
215. (Previously Presented) A polynucleotide according to claim 95 wherein said polynucleotide is RNA.

125
216. (Previously Presented) A polynucleotide according to claim 96 wherein said polynucleotide is RNA.

176
217. (Previously Presented) A polynucleotide according to claim 97 wherein said polynucleotide is RNA.

244
218. (Previously Presented) A polynucleotide according to claim 98 wherein said polynucleotide is RNA.

38
219. (Previously Presented) A polynucleotide according to claim 99 wherein said polynucleotide is RNA.

91
220. (Previously Presented) A polynucleotide according to claim 100 wherein said polynucleotide is RNA.

142
221. (Previously Presented) A polynucleotide according to claim 101 wherein said polynucleotide is RNA.

193
222. (Previously Presented) A polynucleotide according to claim 102 wherein said polynucleotide is RNA.

270
223. (Previously Presented) A polynucleotide according to claim 103 wherein said polynucleotide is labeled.

162
224. (Previously Presented) A polynucleotide according to claim 104 wherein said polynucleotide is labeled.

114

225. (Previously Presented) A polynucleotide according to claim 195 wherein said polynucleotide is labeled.

113165

226. (Previously Presented) A polynucleotide according to claim 196 wherein said polynucleotide is labeled.

164217

227. (Previously Presented) A polynucleotide according to claim 197 wherein said polynucleotide is labeled.

216234

228. (Previously Presented) A polynucleotide according to claim 198 wherein said polynucleotide is labeled.

28328

229. (Previously Presented) A polynucleotide according to claim 199 wherein said polynucleotide is labeled.

227281

230. (Previously Presented) A polynucleotide according to claim 200 wherein said polynucleotide is labeled.

280132

231. (Previously Presented) A polynucleotide according to claim 201 wherein said polynucleotide is labeled.

131183

232. (Previously Presented) A polynucleotide according to claim 202 wherein said polynucleotide is labeled.

182252

233. (Previously Presented) A polynucleotide according to claim 203 wherein said polynucleotide is labeled.

25146

234. (Previously Presented) A polynucleotide according to claim 204 wherein said polynucleotide is labeled.

45

- 98
235. (Previously Presented) A polynucleotide according to claim 205 wherein said polynucleotide is labeled.
- 149
236. (Previously Presented) A polynucleotide according to claim 206 wherein said polynucleotide is labeled.
- 201
237. (Previously Presented) A polynucleotide according to claim 207 wherein said polynucleotide is labeled.
- 262
238. (Previously Presented) A polynucleotide according to claim 208 wherein said polynucleotide is labeled.
- 56
239. (Previously Presented) A polynucleotide according to claim 209 wherein said polynucleotide is labeled.
- 108
240. (Previously Presented) A polynucleotide according to claim 210 wherein said polynucleotide is labeled.
- 159
241. (Previously Presented) A polynucleotide according to claim 211 wherein said polynucleotide is labeled.
- 211
242. (Previously Presented) A polynucleotide according to claim 212 wherein said polynucleotide is labeled.
- 228
243. (Previously Presented) A polynucleotide according to claim 213 wherein said polynucleotide is labeled.
- 22
244. (Previously Presented) A polynucleotide according to claim 214 wherein said polynucleotide is labeled.

74
245. (Previously Presented) A polynucleotide according to claim 215 wherein said polynucleotide is labeled.

124
246. (Previously Presented) A polynucleotide according to claim 216 wherein said polynucleotide is labeled.

177
247. (Previously Presented) A polynucleotide according to claim 217 wherein said polynucleotide is labeled.

245
248. (Previously Presented) A polynucleotide according to claim 218 wherein said polynucleotide is labeled.

39
249. (Previously Presented) A polynucleotide according to claim 219 wherein said polynucleotide is labeled.

92
250. (Previously Presented) A polynucleotide according to claim 220 wherein said polynucleotide is labeled.

143
251. (Previously Presented) A polynucleotide according to claim 221 wherein said polynucleotide is labeled.

273
252. (Previously Presented) A polynucleotide according to any of claims 60-73 wherein said polynucleotide is an oligonucleotide.

63
253. (Previously Presented) A polynucleotide according to claim 74 wherein said polynucleotide is an oligonucleotide.

115
254. (Previously Presented) A polynucleotide according to claim 75 wherein said polynucleotide is an oligonucleotide.

166
285. (Previously Presented) A polynucleotide according to claim 76 wherein said polynucleotide is an oligonucleotide.

218
286. (Previously Presented) A polynucleotide according to claim 77 wherein said polynucleotide is an oligonucleotide.

235
287. (Previously Presented) A polynucleotide according to claim 78 wherein said polynucleotide is an oligonucleotide.

29
288. (Previously Presented) A polynucleotide according to claim 79 wherein said polynucleotide is an oligonucleotide.

82
289. (Previously Presented) A polynucleotide according to claim 80 wherein said polynucleotide is an oligonucleotide.

133
290. (Previously Presented) A polynucleotide according to claim 81 wherein said polynucleotide is an oligonucleotide.

184
291. (Previously Presented) A polynucleotide according to claim 82 wherein said polynucleotide is an oligonucleotide.

253
292. (Previously Presented) A polynucleotide according to claim 83 wherein said polynucleotide is an oligonucleotide.

47
293. (Previously Presented) A polynucleotide according to claim 84 wherein said polynucleotide is an oligonucleotide.

264. 99 (Previously Presented) A polynucleotide according to claim 85 wherein said polynucleotide is an oligonucleotide.

150
265. (Previously Presented) A polynucleotide according to claim 86 wherein said polynucleotide is an oligonucleotide.

202
266. (Previously Presented) A polynucleotide according to claim 87 wherein said polynucleotide is an oligonucleotide.

194
267. (Previously Presented) A polynucleotide according to claim 222 wherein said polynucleotide is labeled.

244
268. (Previously Presented) An oligonucleotide according to claim 252 wherein said oligonucleotide is labeled.

164
269. (Previously Presented) An oligonucleotide according to claim 253 wherein said oligonucleotide is labeled.

116
270. (Previously Presented) An oligonucleotide according to claim 254 wherein said oligonucleotide is labeled.

167
271. (Previously Presented) An oligonucleotide according to claim 255 wherein said oligonucleotide is labeled.

219
272. (Previously Presented) An oligonucleotide according to claim 256 wherein said oligonucleotide is labeled.

234
273. (Previously Presented) An oligonucleotide according to claim 257 wherein said oligonucleotide is labeled.

30
274. (Previously Presented) An oligonucleotide according to claim 258 wherein said oligonucleotide is labeled.

83
275. (Previously Presented) An oligonucleotide according to claim 259 wherein said oligonucleotide is labeled.

134
276. (Previously Presented) An oligonucleotide according to claim 260 wherein said oligonucleotide is labeled.

185
277. (Previously Presented) An oligonucleotide according to claim 261 wherein said oligonucleotide is labeled.

254
278. (Previously Presented) An oligonucleotide according to claim 262 wherein said oligonucleotide is labeled.

48
279. (Previously Presented) An oligonucleotide according to claim 263 wherein said oligonucleotide is labeled.

100
280. (Previously Presented) An oligonucleotide according to claim 264 wherein said oligonucleotide is labeled.

151
281. (Previously Presented) An oligonucleotide according to claim 265 wherein said oligonucleotide is labeled.

203
282. (Previously Presented) An oligonucleotide according to claim 266 wherein said oligonucleotide is labeled.

195
283. (Previously Presented) A polynucleotide according to claim 267 wherein said polynucleotide is an oligonucleotide.

277
284. (Previously Presented) A composition comprising the polynucleotide of any of claims 60-73 wherein said polynucleotide is substantially isolated.

Serial No. 08/441,443
Docket No. 223002006316

285. (Previously Presented) A composition comprising the polynucleotide of claim 74 wherein
said polynucleotide is substantially isolated. 15

286. (Previously Presented) A composition comprising the polynucleotide of claim 75 wherein
said polynucleotide is substantially isolated. 167

287. (Previously Presented) A composition comprising the polynucleotide of claim 76 wherein
said polynucleotide is substantially isolated. 168 119

288. (Previously Presented) A composition comprising the polynucleotide of claim 77 wherein
said polynucleotide is substantially isolated. 220 170

289. (Previously Presented) A composition comprising the polynucleotide of claim 78 wherein
said polynucleotide is substantially isolated. 237 221

290. (Previously Presented) A composition comprising the polynucleotide of claim 79 wherein
said polynucleotide is substantially isolated. 31 14

291. (Previously Presented) A composition comprising the polynucleotide of claim 80 wherein
said polynucleotide is substantially isolated. 24 68

292. (Previously Presented) A composition comprising the polynucleotide of claim 81 wherein
said polynucleotide is substantially isolated. 135 120

293. (Previously Presented) A composition comprising the polynucleotide of claim 82 wherein
said polynucleotide is substantially isolated. 184 171

294. (Previously Presented) A composition comprising the polynucleotide of claim 83 wherein
said polynucleotide is substantially isolated. 255 29

- 49
295. (Previously Presented) A composition comprising the polynucleotide of claim 84 wherein said polynucleotide is substantially isolated. 33
- 101
296. (Previously Presented) A composition comprising the polynucleotide of claim 85 wherein said polynucleotide is substantially isolated. 84
- 152
297. (Previously Presented) A composition comprising the polynucleotide of claim 86 wherein said polynucleotide is substantially isolated. 137
- 204
298. (Previously Presented) A composition comprising the polynucleotide of claim 87 wherein said polynucleotide is substantially isolated. 188
- 243
299. (Previously Presented) A composition comprising the polynucleotide of claim 88 wherein said polynucleotide is substantially isolated. 257
- 57
300. (Previously Presented) A composition comprising the polynucleotide of claim 89 wherein said polynucleotide is substantially isolated. 51
- 109
301. (Previously Presented) A composition comprising the polynucleotide of claim 90 wherein said polynucleotide is substantially isolated. 103
- 160
302. (Previously Presented) A composition comprising the polynucleotide of claim 91 wherein said polynucleotide is substantially isolated. 154
- 212
303. (Previously Presented) A composition comprising the polynucleotide of claim 92 wherein said polynucleotide is substantially isolated. 204
- 229
304. (Previously Presented) A composition comprising the polynucleotide of claim 93 wherein said polynucleotide is substantially isolated. 273

23
305. (Previously Presented) A composition comprising the polynucleotide of claim 94 wherein said polynucleotide is substantially isolated.

25
306. (Previously Presented) A composition comprising the polynucleotide of claim 95 wherein said polynucleotide is substantially isolated.

127
307. (Previously Presented) A composition comprising the polynucleotide of claim 96 wherein said polynucleotide is substantially isolated.

178
308. (Previously Presented) A composition comprising the polynucleotide of claim 97 wherein said polynucleotide is substantially isolated.

246
309. (Previously Presented) A composition comprising the polynucleotide of claim 98 wherein said polynucleotide is substantially isolated.

40
310. (Previously Presented) A composition comprising the polynucleotide of claim 99 wherein said polynucleotide is substantially isolated.

93
311. (Previously Presented) A composition comprising the polynucleotide of claim 100 wherein said polynucleotide is substantially isolated.

144
312. (Previously Presented) A composition comprising the polynucleotide of claim 101 wherein said polynucleotide is substantially isolated.

194
313. (Previously Presented) A composition comprising the polynucleotide of claim 102 wherein said polynucleotide is substantially isolated.

219
314. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of any of claims 60-73 in a suitable package.

315. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 74 in a suitable package.

316. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 75 in a suitable package.

317. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 76 in a suitable package.

318. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 77 in a suitable package.

319. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 78 in a suitable package.

320. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 79 in a suitable package.

321. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 80 in a suitable package.

322. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 81 in a suitable package.

323. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 82 in a suitable package.

324. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 83 in a suitable package.

5¹⁰
325. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 84 in a suitable package.

10²
326. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 85 in a suitable package.

15³
327. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 86 in a suitable package.

20⁵
328. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 87 in a suitable package.

26⁴
329. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 88 in a suitable package.

7⁶
330. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 89 in a suitable package.

4¹
331. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 90 in a suitable package.

24⁹
332. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 113 in a suitable package.

28¹
333. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 117 in a suitable package.

26⁸
334. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 133 in a suitable package.

272
335. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim *261* in a suitable package.

271
336. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim *270* in a suitable package.

274
337. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim *273* in a suitable package.

278
338. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim *277* in a suitable package.

275
339. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim *274* in a suitable package.

280
340. (Previously Presented) A polynucleotide of any of claims *60-73* wherein said polynucleotide encodes a polypeptide having a sequence comprising at least 10 contiguous amino acids from an HCV1 polyprotein.

282
341. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that contain a detectable polynucleotide comprising a contiguous sequence of at least 15 nucleotides fully complementary to either strand of Figure 3.

283
342. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that contain a detectable polynucleotide comprising a contiguous sequence of at least 15 nucleotides fully complementary to either strand of Figure 62A.

284
343. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that contain a

detectable polynucleotide comprising a contiguous sequence of at least 15 nucleotides fully complementary to either strand of Figure 89.

285
344. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise a polynucleotide that hybridizes under stringent conditions to a polynucleotide that comprises a contiguous sequence of at least 15 nucleotides from the genome of a hepatitis C virus genome or the complement thereof.

286
345. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise a polynucleotide that hybridizes under stringent conditions to a contiguous sequence of at least 15 nucleotides from either strand of at least one of the HCV cDNA inserts in a lambda gt-11 cDNA library deposited as ATCC No. 40394.

287
346. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise a polynucleotide that hybridizes under stringent conditions to a contiguous sequence of at least 15 nucleotides found in either strand of Figure 89.

288
347. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise a polynucleotide that hybridizes under stringent conditions to a contiguous sequence of at least 15 nucleotides found in either strand of Figure 14.

289
348. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise a polynucleotide that hybridizes under stringent conditions to a contiguous sequence of at least 15 nucleotides from either strand of Figure 58.

292
349. (Previously Presented) A method according to any of claims 344-348 wherein said selected samples comprise said polynucleotide and said stringent conditions permit the formation of a stable hybrid duplex between said polynucleotide and said contiguous

sequence and do not permit the formation of a stable duplex between said contiguous sequence and the genomes of Hepatitis B or Hepatitis A viruses.

350. Canceled.

²⁹³ 351. (Previously Presented) A method according to claim ²⁹² 349 wherein said polynucleotide is detectable in a PCR assay.

³⁰⁰ 352. (Previously Presented) A method according to claim ²⁹² 349 wherein said biological samples are blood.

353. Canceled.

²⁹⁴ 354. (Previously Presented) A method according to claim ²⁹³ 351 wherein said biological samples are blood.

³⁰⁴ 355. (Previously Presented) A method according to claim ²⁹² 349 wherein said biological samples are plasma.

356. Canceled.

²⁹⁶ 357. (Previously Presented) A method according to claim ²⁹³ 351 wherein said biological samples are plasma.

~~307~~ 358. (Previously Presented) A method according to claim ²⁹² 349 wherein said biological samples are sera.

359. Canceled.

²⁹⁸ 360. (Previously Presented) A method according to claim ²⁹³ 351 wherein said biological samples are sera.

³⁰¹ 361. (Previously Presented) A method according to claim ³⁰⁰ 352 further comprising employing biological samples that are not selected for a preparation of blood-related products.

³⁰⁵ 362. (Previously Presented) A method according to claim ³⁰⁴ 355 further comprising employing biological samples that are not selected for a preparation of blood-related products.

302 363. (Previously Presented) A method according to claim 352 further comprising preparing polyclonal antibodies with selected biological samples.

300 364. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that contain a detectable polynucleotide comprising a sequence that is fully complementary to a contiguous sequence of at least 15 nucleotides from the genome of a hepatitis C virus genome or the complement thereof.

291 365. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that contain a detectable polynucleotide comprising a sequence that is fully complementary to a contiguous sequence of at least 15 nucleotides from either strand of at least one of the HCV cDNA inserts in a lambda gt- 11 cDNA library deposited as A TCC No. 40394.

303 366. (Previously Presented) A method according to claim 352 wherein the selecting is to identify an HCV positive sample for removal from the supply.

367. Canceled.

295 368. (Previously Presented) A method according to claim 354 wherein the selecting is to identify an HCV positive sample for removal from the supply.

304 369. (Previously Presented) A method according to claim 355 wherein the selecting is to identify an HCV positive sample for removal from the supply.

370. Canceled.

297 371. (Previously Presented) A method according to claim 357 wherein the selecting is to identify an HCV positive sample for removal from the supply.

308 372. (Previously Presented) A method according to claim 358 wherein the selecting is to identify an HCV positive sample for removal from the supply.

373. Canceled.

299 374. (Previously Presented) A method according to claim 360 wherein the selecting is to identify an HCV positive sample for removal from the supply.

375 375. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides from the genome of a hepatitis C virus genome or the complement thereof.

376 376. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides from the genome of a hepatitis C virus genome or the complement thereof.

377 377. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides from either strand of at least one of the HCV cDNA inserts in a lambda gt-11 cDNA library deposited as A TCC No. 40394.

378 378. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides from either strand of at least one of the HCV cDNA inserts in a lambda gt-11 cDNA library deposited as ATCC No. 40394.

379 379. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second

polynucleotide that comprises a contiguous sequence of at least 15 nucleotides found in Figure 89, or the complement thereof.

~~373~~ 373
380. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides found in Figure 89, or the complement thereof.

~~374~~ 374
381. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides found in either strand of Figure 58.

~~374~~ 374
382. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides found in either stand of Figure 58.

~~375~~ 375
383. (Previously Presented) A method according to any of claims 375, 377, 379, 381 wherein said selected samples comprise said first polynucleotide and said stringent conditions permit the formation of a stable hybrid duplex between said first polynucleotide and said contiguous sequence of nucleotides and do not permit the formation of a stable duplex between said contiguous sequence and the genomes of Hepatitis B or Hepatitis A viruses.

~~375~~ 375
384. (Previously Presented) A method according to any of claims 376, 378, 380, 382 wherein said selected samples do not comprise said first polynucleotide and said stringent conditions permit the formation of a stable hybrid duplex between said first polynucleotide and said contiguous sequence and do not permit the formation of a stable duplex between said contiguous sequence and the genomes of Hepatitis B or Hepatitis A viruses.

~~385.~~ (Previously Presented) A method according to claim ~~383~~, wherein said stringent conditions include using 50% (w/v) formamide and washing in 5xSSC, 0.1 % SDS at 55 DC.

~~386.~~ (Previously Presented) A method according to claim ~~384~~, wherein said stringent conditions include using 50% (w/v) formamide and washing in 5xSSC, 0.1 % SDS at 55 DC.

~~387.~~ (Previously Presented) A method according to claim ~~383~~ wherein said first polynucleotide is detectable in a PCR assay.

~~388.~~ (Previously Presented) A method according to ~~385~~, wherein said first polynucleotide is detectable in a PCR assay.

~~389.~~ (Previously Presented) A method according to claim ~~384~~ wherein said first polynucleotide is not detectable in a PCR assay.

~~390.~~ (Previously Presented) A method according to claim ~~386~~ wherein said first polynucleotide is not detectable in a PCR assay.

~~391.~~ (Previously Presented) A method according to any of claims ~~375-382~~ wherein said biological samples are blood.

~~392.~~ (Previously Presented) A method according to claim ~~383~~ wherein said biological samples are blood.

~~393.~~ (Previously Presented) A method according to claim ~~384~~ wherein said biological samples are blood.

~~394.~~ (Previously Presented) A method according to claim ~~385~~ wherein said biological samples are blood.

~~395.~~ (Previously Presented) A method according to claim ~~386~~ wherein said biological samples are blood.

~~396.~~ (Previously Presented) A method according to claim ~~387~~ wherein said biological samples are blood.

348
350
397. (Previously Presented) A method according to claim 388 wherein said biological samples are blood.

400 389
398. (Previously Presented) A method according to claim 389 wherein said biological samples are blood.

400 378
399. (Previously Presented) A method according to claim 390 wherein said biological samples are blood.

402
400. (Previously Presented) A method according to any of claims 375-382 wherein said biological samples are plasma.

375 365
401. (Previously Presented) A method according to claim 383 wherein said biological samples are plasma.

445 395
402. (Previously Presented) A method according to claim 384 wherein said biological samples are plasma.

360 354
403. (Previously Presented) A method according to claim 385 wherein said biological samples are plasma.

404. (Previously Presented) A method according to claim 386 wherein said biological samples are plasma.

370 360
405. (Previously Presented) A method according to claim 387 wherein said biological samples are plasma.

370 349
406. (Previously Presented) A method according to claim 388 wherein said biological samples are plasma.

370 390
407. (Previously Presented) A method according to claim 389 wherein said biological samples are plasma.

370 379
408. (Previously Presented) A method according to claim 390 wherein said biological samples are plasma.

403
409. (Previously Presented) A method according to any of claims 375-382 wherein said biological samples are sera.

360
410. (Previously Presented) A method according to claim 383 wherein said biological samples are sera.

361
411. (Previously Presented) A method according to claim 384 wherein said biological samples are sera.

362
412. (Previously Presented) A method according to claim 385 wherein said biological samples are sera.

363
413. (Previously Presented) A method according to claim 386 wherein said biological samples are sera.

364
414. (Previously Presented) A method according to claim 387 wherein said biological samples are sera.

365
415. (Previously Presented) A method according to claim 388 wherein said biological samples are sera.

366
416. (Previously Presented) A method according to claim 389 wherein said biological samples are sera.

367
417. (Previously Presented) A method according to claim 390 wherein said biological samples are sera.

368
418. (Previously Presented) A method according to any of claims 375, 377, 379 or 381 further comprising employing biological samples that are not selected for a preparation of blood-related products.

369
419. (Previously Presented) A method according to claim 383 further comprising employing biological samples that are not selected for a preparation of blood-related products.

370
420. (Previously Presented) A method according to claim 385 further comprising employing biological samples that are not selected for a preparation of blood-related products.

~~362~~ 358
421. (Previously Presented) A method according to claim 387 further comprising employing biological samples that are not selected for a preparation of blood-related products.

~~361~~ 359 367
422. (Previously Presented) A method according to claim 386 further comprising employing biological samples that are not selected for a preparation of blood-related products.

~~361~~ 399 371-374
423. (Previously Presented) A method according to any of claims 376, 378, 380 or 382 further comprising employing biological samples that are selected for a preparation of blood-related products.

~~361~~ 397 375
424. (Previously Presented) A method according to claim 384 further comprising employing biological samples that are selected for a preparation of blood-related products.

~~361~~ 384 376
425. (Previously Presented) A method according to claim 385 further comprising employing biological samples that are not selected for a preparation of blood-related products.

~~361~~ 392 378
426. (Previously Presented) A method according to claim 389 further comprising employing biological samples that are not selected for a preparation of blood-related products.

~~361~~ 391 377
427. (Previously Presented) A method according to claim 390 further comprising employing biological samples that are not selected for a preparation of blood-related products.

~~361~~ 407 371-374
428. (Previously Presented) A method according to any of claims 376, 378, 380 or 382 wherein said selected samples are supply samples for preparation of blood products.

~~361~~ 398 375
429. (Previously Presented) A method according to claim 384 wherein said selected samples are supply sample for preparation of blood products.

~~361~~ 387 376
430. (Previously Presented) A method according to claim 386 wherein said selected samples are supply sample for preparation of blood products.

~~361~~ 393 388
431. (Previously Presented) A method according to claim 389 wherein said selected samples are supply sample for preparation of blood products.

~~361~~ 395 377
432. (Previously Presented) A method according to claim 390 wherein said selected samples are supply sample for preparation of blood products.

390

351-354

433. (Previously Presented) A method according to any of claims 375, 377, 379 or 381 wherein said samples that are not selected are supply samples for preparation of blood products.

388

355

434. (Previously Presented) A method according to claim 383 wherein said samples that are not selected are supply samples for preparation of blood products.

367

356

435. (Previously Presented) A method according to claim 385 wherein said samples that are not selected are supply samples for preparation of blood products.

373

368

436. (Previously Presented) A method according to claim 387 wherein said samples that are not selected are supply samples for preparation of blood products.

362

357

437. (Previously Presented) A method according to claim 388 wherein said samples that are not selected are supply samples for preparation of blood products.

374

282 - 291

374

374

Please add the following new claims:

438. (New) A method according to any of claims 341-348, 364 or 365 wherein said polynucleotide is detectable in a PCR assay.

375

374

374

439. (New) A method according to claim 438 wherein said biological samples are blood.

377

374

374

440. (New) A method according to claim 438 wherein said biological samples are plasma.

379

374

374

441. (New) A method according to claim 438 wherein said biological samples are sera.

376

375

375

375

375

375

375

375

375

375

375

375

375

375

375

375

375

375

375

375

375

375

- 340 339
444 (New) A method according to claim 441 wherein the selecting is to identify an HCV positive sample for removal from the supply.
- 322 282-289
445. (New) A method according to claims 344-348, wherein said stringent conditions include using 50% (w/v) formamide and washing in 5xSSC, 0.1 % SDS at 55 DC.
- 310 292
446. (New) A method according to claim 349 wherein said stringent conditions include using 50% (w/v) formamide and washing in 5xSSC, 0.1 % SDS at 55 DC.
- 323 322
447. (New) A method according to claim 445 wherein said polynucleotide is detectable in a PCR assay.
- 311 310
448. (New) A method according to claim 446 wherein said polynucleotide is detectable in a PCR assay.
- 329 322
449. (New) A method according to claim 445 wherein said biological samples are blood.
- 317 310
450. (New) A method according to claim 446 wherein said biological samples are blood.
- 330 322
451. (New) A method according to claim 445 wherein said biological samples are plasma.
- 318 310
452. (New) A method according to claim 446 wherein said biological samples are plasma.
- 331 322
453. (New) A method according to claim 445 wherein said biological samples are sera.
- 319 315
454. (New) A method according to claim 446 wherein said biological samples are sera.
- 324 323
455. (New) A method according to claim 447 wherein said biological samples are blood.
- 312 311
456. (New) A method according to claim 448 wherein said biological samples are blood.
- 325 323
457. (New) A method according to claim 447 wherein said biological samples are sera.
- 313 311
458. (New) A method according to claim 448 wherein said biological samples are sera.
- 326 323
459. (New) A method according to claim 447 wherein said biological samples are plasma.
- 314 311
460. (New) A method according to claim 448 wherein said biological samples are plasma.

332 461. (New) A method according to claim *445* further comprising employing biological samples that are not selected for a preparation of blood-related products.

320 462. (New) A method according to claim *446* further comprising employing biological samples that are not selected for a preparation of blood-related products.

327 463. (New) A method according to claim *447* further comprising employing biological samples that are not selected for a preparation of blood-related products.

315 464. (New) A method according to claim *448* further comprising employing biological samples that are not selected for a preparation of blood-related products.

333 465. (New) A method according to claim *445* wherein said samples that are not selected are supply samples for preparation of blood products.

321 466. (New) A method according to claim *446* wherein said samples that are not selected are supply samples for preparation of blood products.

328 467. (New) A method according to claim *447* wherein said samples that are not selected are supply samples for preparation of blood products.

316 468. (New) A method according to claim *448* wherein said samples that are not selected are supply samples for preparation of blood products.

309 469. (New) A method according to claim *358* further comprising employing biological samples that are not selected for a preparation of blood-related products.